CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential

Area of Science:

• Ophthalmology
• Oncology
• Genetics

Background:

• Primary vitreoretinal lymphoma (PVRL) is a rare ocular lymphoma with diagnostic challenges due to limited biopsy samples.
• PVRL has a poor prognosis and a high risk of progression to central nervous system (CNS) lymphoma.
• MYD88^L265P and CD79B^Y196 mutations are frequently found in primary CNS lymphoma (PCNSL) and are associated with PVRL.

Purpose of the Study:

• To investigate the diagnostic and prognostic potential of MYD88^L265P and CD79B^Y196 mutations in patients with PVRL.
• To analyze the presence of these mutations in vitreous fluid DNA for early detection and risk stratification.

Main Methods:

• Direct sequencing and allele-specific polymerase chain reaction were used to detect mutations.
• DNA was extracted from the vitreous fluid of 17 PVRL patients at diagnosis.
• Retrospective analysis of prognostic potential was performed.

Main Results:

• CD79B^Y196 mutations were found in 35% (6/17) of PVRL patients.
• MYD88^L265P mutations were detected in 71% (12/17) of PVRL patients.
• Patients with CD79B^Y196 mutations developed CNS disease significantly earlier (16.5 months) compared to those with wild-type CD79B (67 months).

Conclusions:

• Detection of CD79B^Y196 mutations in vitreous DNA can aid in confirming PVRL diagnosis.
• CD79B^Y196 mutation status may serve as a prognostic marker for predicting CNS involvement in PVRL.